Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Short interest is the total number of shares lent out as per latest regulatory filings. Updated twice a month per FINRA reporting.

Short float is the total number of shares currently held as short positions divided by the total float as per latest regulatory filings. Updated twice a month per FINRA reporting.

Short float

Shorting

Short interest

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Earnings data Q3 2026

Earnings data Q4 2026

Earnings data Q1 2027

Earnings data Q2 2027

Earnings data Q3 2027

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Doximity excels in Q3 with record revenue and user engagement

Doximity's Q3 performance reflects strong revenue growth, profitability, and user engagement, positioning the company well in the digital healthcare market.
The company's recognition as a top telehealth platform, successful product launches, and AI utilization highlight its competitive strengths.
Challenges include sustaining growth rates, managing costs, and adapting to market dynamics, while opportunities lie in market expansion and innovation.
Overall, Doximity's strategic focus on growth and customer-centric initiatives bodes well for its future success in the evolving healthcare landscape.

Doximity surpasses revenue targets, eyes AI growth and disciplined investments

Doximity delivered strong financial performance in Q4 2025, exceeding revenue guidance and showcasing robust EBITDA margins. The company's emphasis on AI tools, client engagement, and disciplined investment approach positions it well for future growth. With a healthy cash position and a focus on market expansion, Doximity is poised for continued success in the healthcare technology sector.

Doximity excels in Q2, eyes AI growth amid budget uncertainties

Doximity's Q2 performance showcases robust revenue growth, strong network engagement, and successful AI integration, driving an optimistic outlook for the company. While facing budget uncertainties and AI investment challenges, Doximity's focus on client engagement and technological innovation positions it well for future growth. The company's strategic strengths in pharma business, AI solutions, and user adoption underscore its potential for sustained success and market leadership.

Doximity excels in Q3 with strong financials and AI adoption

Doximity's Q3 2026 earnings call highlighted robust financial performance, strong AI product adoption, and a focus on physician-centric AI tools. While facing challenges from policy changes impacting budget decisions, the company remains optimistic about future growth and upsell opportunities. Strategic investments in AI technology, market expansion, and maintaining high EBITDA margins underscore Doximity's commitment to innovation and financial stability.

Doximity surpasses Q4 expectations, navigates market challenges with AI

Doximity's Q4 performance exceeded expectations with strong financials and AI growth. Challenges in soft market environment and regulatory concerns require strategic navigation. Opportunities lie in AI-driven innovations, new TAM creation, and maintaining strong margins. New leadership appointments signal a focus on continued growth and market differentiation.

Doximity reports robust Q1 earnings, leads in AI healthcare innovation

Doximity's Q1 '27 performance showcased revenue growth, strong AI usage, and prudent financial management, positioning the company for future success. While facing challenges in a competitive landscape, Doximity's focus on AI investments and client expansion presents significant growth opportunities. With a solid financial foundation and a commitment to AI innovation, Doximity is well-equipped to navigate challenges and capitalize on emerging opportunities in the healthcare AI market.

Doximity beats Q2 estimates, raises guidance as AI search gains traction

Doximity reported Q2 FY2027 revenue of $174.5 million, up 4% year-over-year and above the high end of guidance, while adjusted EBITDA of $89 million (51% margin) came in 9% above the top of guidance, aided by improving AI cost efficiency. The company raised its full-year FY2027 revenue guidance to $678M–$683M (~6% growth) and its adjusted EBITDA guidance to $317M–$325M. Quarterly active workflow prescribers hit record highs, growing 34% year-over-year, with approximately half of all 1.8 million U.S. prescribers now using Doximity's workflow tools. The AI search product reached 8-figure bookings with 16 of the top 20 pharma companies already signed, pointing to entry into the ~$14 billion pharma paid search market.